Magdalena Harris1, Tim Rhodes. 1. Centre for Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine, London, UK. magdalena.harris@lshtm.ac.uk
Abstract
AIM: To explore the facilitators of long-term hepatitis C avoidance among people who inject drugs. DESIGN: We employed a qualitative life history design. SETTING: Recruitment took place through low-threshold drug services and drug user networks in South East and North London. Participants were interviewed at the recruitment services or in their homes. PARTICIPANTS: The sample comprised 35 people who inject drugs, 20 of whom were hepatitis C antibody-negative. Participants' average injecting trajectory was 19 years (6-33), with 66% primarily injecting heroin, and 34% a crack and heroin mix. Nine (26%) of the sample were female and the average age was 39 years (23-53). MEASUREMENTS: Two interviews were conducted with each participant, with the second interview incorporating reference to a computer-constructed life history time-line. Interview accounts were audiorecorded, transcribed verbatim and analysed thematically. FINDINGS: Hepatitis C risk awareness was recent and deprioritized by the majority of participants. The facilitation of venous access and care was an initial and enduring rationale for safe injecting practices. Difficult venous access resulted in increased contamination of injecting environments and transitions to femoral injecting. Participants expressed an unmet desire for non-judgemental venous access information and advice. CONCLUSIONS: Harm reduction interventions which attend to the immediate priorities of people who inject drugs, such as venous access and care, have the potential to re-engage individuals who are jaded or confused by hepatitis C prevention messages.
AIM: To explore the facilitators of long-term hepatitis C avoidance among people who inject drugs. DESIGN: We employed a qualitative life history design. SETTING: Recruitment took place through low-threshold drug services and drug user networks in South East and North London. Participants were interviewed at the recruitment services or in their homes. PARTICIPANTS: The sample comprised 35 people who inject drugs, 20 of whom were hepatitis C antibody-negative. Participants' average injecting trajectory was 19 years (6-33), with 66% primarily injecting heroin, and 34% a crack and heroin mix. Nine (26%) of the sample were female and the average age was 39 years (23-53). MEASUREMENTS: Two interviews were conducted with each participant, with the second interview incorporating reference to a computer-constructed life history time-line. Interview accounts were audiorecorded, transcribed verbatim and analysed thematically. FINDINGS: Hepatitis C risk awareness was recent and deprioritized by the majority of participants. The facilitation of venous access and care was an initial and enduring rationale for safe injecting practices. Difficult venous access resulted in increased contamination of injecting environments and transitions to femoral injecting. Participants expressed an unmet desire for non-judgemental venous access information and advice. CONCLUSIONS: Harm reduction interventions which attend to the immediate priorities of people who inject drugs, such as venous access and care, have the potential to re-engage individuals who are jaded or confused by hepatitis C prevention messages.
Authors: Andy Guise; Jason Melo; Maria Luisa Mittal; Claudia Rafful; Jazmine Cuevas-Mota; Peter Davidson; Richard S Garfein; Dan Werb Journal: Int J Drug Policy Date: 2018-03-07
Authors: Daniel Ciccarone; George Jay Unick; Jenny K Cohen; Sarah G Mars; Daniel Rosenblum Journal: Drug Alcohol Depend Date: 2016-04-14 Impact factor: 4.492
Authors: Pedro Mateu-Gelabert; Lauren Jessell; Elizabeth Goodbody; Dongah Kim; Krista Gile; Jennifer Teubl; Cassandra Syckes; Kelly Ruggles; Jeffrey Lazar; Sam Friedman; Honoria Guarino Journal: Int J Drug Policy Date: 2017-05-31
Authors: Yoelkys Morales; Emma Smyth; Julia Zubiago; Benjamin Bearnot; Alysse G Wurcel Journal: Open Forum Infect Dis Date: 2022-10-19 Impact factor: 4.423
Authors: Natasha K Martin; Matthew Hickman; Alec Miners; Sharon J Hutchinson; Avril Taylor; Peter Vickerman Journal: BMJ Open Date: 2013-08-13 Impact factor: 2.692